Tezepelumab Reduces Asthma Exacerbations by 49% in Real-World Use

This report highlights that tezepelumab treatment in real-world settings led to a 49% reduction in asthma exacerbations, along with decreased healthcare utilization and costs. The benefits were notably greater in patients who were biologic-naïve and those with high eosinophil counts, indicating targeted effectiveness in these subgroups.

Originally published by gnews